Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises

Syndax Pharmaceuticals reported stronger-than-expected Q2 2025 results, posting a narrower loss per share of -$0.83 and revenue of $37.96 million, significantly exceeding analyst forecasts and driving a 4.01% aftermarket stock increase. This performance was largely attributed to robust sales of its key products, RevuForge and Nyktimbo, which generated nearly $100 million combined in H1 2025. With a strong liquidity position of $518 million in cash and stable operating expenses, the company anticipates achieving profitability with its current funds, while the upcoming October 25, 2025 PDUFA date for RevuForge's NPM1 AML expansion is poised to significantly broaden its addressable market and accelerate revenue growth.

Analysis

Syndax Pharmaceuticals delivered a significantly strong second quarter for 2025, beating consensus estimates on both revenue and earnings per share. Revenue of $37.96 million surpassed forecasts by nearly 40%, driven by robust commercial execution for its two key assets. RevuForge, its treatment for KMT2A acute leukemia, saw net revenue grow 43% quarter-over-quarter to $28.6 million, having already penetrated 25% of its initial target market within seven months of launch. Critically, commercial data indicates a shift to earlier lines of therapy and a one-third transplant rate, higher than in clinical trials, suggesting a potential for a meaningful increase in the average duration of therapy from the current 4-6 month projection to 6-12 months in the second year. The second product, Nyktimbo, for which Syndax shares profits with Incyte, is already a positive cash flow contributor to Syndax in its first full quarter, generating $9.4 million in collaboration revenue. Financially, the company is well-capitalized with $518 million in cash and has provided crucial guidance that it expects to reach profitability on current funds while maintaining stable operating expenses, substantially de-risking its financial profile. The primary near-term catalyst is the PDUFA date of October 25, 2025, for RevuForge's label expansion into NPM1 AML, an approval which would triple the addressable patient population from 2,000 to over 6,000.

Key Decisions for Investors

• Given the dual-product outperformance and management's guidance for reaching profitability on existing capital, investors should assess the stock's current valuation relative to its de-risked financial profile and accelerating growth trajectory.
• The October 25, 2025 PDUFA date for RevuForge's label expansion into the larger NPM1 AML market represents the most significant near-term catalyst and a critical inflection point for future revenue growth.
• Investors should monitor the evolution of RevuForge's average treatment duration, as the stated trends of earlier-line use and post-transplant maintenance are key long-term value drivers that could lead to upward revisions in revenue forecasts.
• Track the company's ability to maintain stable operating expenses in subsequent quarters, as adherence to this guidance alongside continued revenue ramp is fundamental to the thesis of achieving self-sustainability without future dilution.